Bristol Myers Squibb (Celgene) Deal History & Licensing Activity
Bristol Myers Squibb (Celgene) is a large pharma headquartered in US. Over the past three years, Bristol Myers Squibb (Celgene) has been involved in 13 licensing and acquisition transactions, with a primary focus on Other (12 deals). The company currently has 10 active clinical trials, primarily in Oncology.
Deals (12mo)
4
Active Trials
10
Top Modality
Other
Focus Area
Oncology
Bristol Myers Squibb (Celgene) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Bristol Myers Squibb (Celgene) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Hengrui multi-asset portfolio (up to 13 drugs) | Bristol Myers Squibb | Other | Unknown | collaboration | Jun 15, 2026 |
| 13 early-stage oncology/hematology/immunology programs | Bristol Myers Squibb | Other | Discovery | collaboration | Jun 12, 2026 |
| 13 programs (including 5 jointly discovered assets) | Bristol Myers Squibb | Other |
Bristol Myers Squibb (Celgene) Pipeline Focus
Therapeutic areas and modalities where Bristol Myers Squibb (Celgene) is most active based on deal history and clinical trial data.
Therapeutic Areas
Bristol Myers Squibb (Celgene) Clinical Pipeline
Bristol Myers Squibb (Celgene) has 10 active clinical trials across 4 development phases.
2
Unknown
3
Phase 1
2
Phase 2
3
Phase 3
See How Your Asset Matches Bristol Myers Squibb (Celgene)'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Bristol Myers Squibb (Celgene) Licensing & Deal Activity
Bristol Myers Squibb (Celgene) is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 13 deals over the past three years, Bristol Myers Squibb (Celgene) ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Bristol Myers Squibb (Celgene) include Oncology (11 deals and trials), Hematological Malignancies (5 deals and trials), Immunology (2 deals and trials), and Autoimmune (2 deals and trials). In terms of modality, Bristol Myers Squibb (Celgene) has shown particular interest in other, small molecules, bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Bristol Myers Squibb (Celgene) and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Bristol Myers Squibb (Celgene)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.